Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single‐center experience of eight patients

Z Liu, Y Xiao, J Xu, M Liu, M Han… - Laryngoscope …, 2023 - Wiley Online Library
Recurrent respiratory papillomatosis (RRP) is a human papilloma virus (HPV)‐driven benign
neoplasm, affecting larynx, trachea, and even lung, leading to voice disorders, airway …

Advances in Recurrent Respiratory Papillomatosis Treatment: Adjuvant Intralesional Bevacizumab's Impact, Potential and Insights from a Case Series Study

D Nayani, M Kasireddy, T Shankar, PAR Kumar… - Indian Journal of …, 2024 - Springer
Recurrent respiratory papillomatosis is an aggressive benign disease characterised by the
repeated growth of multiple warts involving the larynx as well as other parts of the respiratory …

Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children

C Carnevale, L Ferrán‐De la Cierva… - The …, 2019 - Wiley Online Library
Recurrent respiratory papillomatosis can be a devastating condition for a child, with severe
consequences. Currently, there is no proven successful medical treatment. We describe the …

Systemic bevacizumab for treatment of recurrent respiratory papillomatosis

X Zhao, J Wang, Q Chen, X Wu, W Mao, J Ma… - European Archives of …, 2024 - Springer
Objectives To characterize treatment response of recurrent respiratory papillomatosis (RRP)
including adult-onset RRP (AORRP) and juvenile-onset RRP (JORRP) to systemic …

Recurrent respiratory papillomatosis

R Ruiz, KB Zur - Current Otorhinolaryngology Reports, 2021 - Springer
Abstract Purpose of Review Recurrent respiratory papillomatosis (RRP) is a rare disease
that continues to cause significant morbidity and occupies a disproportionate amount of …

Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis

SR Best, AD Friedman… - Annals of Otology …, 2012 - journals.sagepub.com
Objectives: Increasing evidence supports the use of laryngeal injections of the
antiangiogenic agent bevacizumab (Avastin) for the adjuvant treatment of recurrent …

Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled pilot study

Y Ablanedo-Terrazas, O Estrada-Camacho… - Acta …, 2022 - Elsevier
Objectives After surgical resection of papilloma, adjuvant therapy may be recommended for
the control of recurrent respiratory papillomatosis (RRP). As the efficacy of adjuvant therapy …

Systemic bevacizumab (avastin) for juvenile‐onset recurrent respiratory papillomatosis: a systematic review

MA Ryan, GR Leu, PA Upchurch, DE Tunkel… - The …, 2021 - Wiley Online Library
Objectives Juvenile onset recurrent respiratory papillomatosis (JORRP) can cause severe or
disseminated disease. Surgical treatment may be inadequate. Systemic bevacizumab has …

Healthcare Spending and Systemic Bevacizumab for Recurrent Respiratory Papillomatosis

AD Schuman, AC Chapel, P You, R Venkatramani… - Journal of Voice, 2024 - Elsevier
Objectives Juvenile-onset recurrent respiratory papillomatosis (JoRRP) is a rare, costly
condition linked to human papillomavirus. Standard of care is serial surgical debridement …

Recurrent Respiratory Papillomatosis With Complete Response to Systemic Bevacizumab Therapy

D Gorelik, A Frantz, JS Dome… - Ear, Nose & Throat …, 2024 - journals.sagepub.com
Recurrent respiratory papillomatosis is a condition caused by human papilloma virus,
usually sub types 6 and 11. Papillomas are benign neoplasms that are most commonly …